CLEO Establishes U.S. Reimbursement Pathway
Filed with ASX · · 3 pages · English
Summary by 6ix AI
CLEO Diagnostics Ltd has announced the establishment of a reimbursement pathway for its Pre-Surgical Ovarian Cancer Test in the U.S. market, which will allow for immediate billing following FDA clearance. The company plans to utilize a miscellaneous CPT code to facilitate early revenue generation and clinical adoption while working towards a dedicated CPT code for long-term reimbursement. This strategy aims to support the collection of real-world utilization data and evidence generation to strengthen future reimbursement applications.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from CLEO Diagnostics
- CLEO Commences Kit Manufacturing Ahead of FDA Submission
- Sample Collection Completion for Pivotal US Clinical Trial
- CLEO Optimises Biomarker Panel Ahead of FDA Submission
- Appendix 4D and Half Yearly Accounts
- CLEO Confirms Next-Gen Platform for Ovarian Cancer Test
Later from CLEO Diagnostics
- CLEO Enters Analytical Validation Phase
- Appendix 4E and 2026 Annual Report
- CLEO Receives First Batch of Commercial Test Kits
- CLIA Certified Lab selected - Pivotal US Clinical Validation
- CLEO Commences Ovarian Cancer Screening Test Development
Follow CLEO Diagnostics into a list and get an email when it puts out news.
Follow CLEO Diagnostics